Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
- Amr El Zawily (14851115)
- Frederick S. Vizeacoumar (14851118)
- Renuka Dahiya (14851121)
- Sara L. Banerjee (14851124)
- Kalpana K. Bhanumathy (14851127)
- Hussain Elhasasna (14851130)
- Glinton Hanover (14851133)
- Jessica C. Sharpe (14851136)
- Malkon G. Sanchez (14851139)
- Paul Greidanus (14851142)
- R. Greg Stacey (14851145)
- Kyung-Mee Moon (14851148)
- Ilya Alexandrov (14851151)
- Juha P. Himanen (14851154)
- Dimitar B. Nikolov (14851157)
- Humphrey Fonge (14851160)
- Aaron P. White (14851163)
- Leonard J. Foster (8976302)
- Bingcheng Wang (14851166)
- Behzad M. Toosi (14851169)
- Nicolas Bisson (14851172)
- Tajib A. Mirzabekov (14851175)
- Franco J. Vizeacoumar (14851178)
- Andrew Freywald (14851181)
Publication date
July 2023
DOI Publisher
American Association for Cancer Research (AACR)Abstract
Table S1: Phosphorylated proteins expressed differently in αEPHA2-Cond and cIgG-Tr cells.</p
Add to ORKG